Drugs for Supranuclear Palsy, Progressive, 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 108)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Zolpidem |
Approved |
Phase 4 |
|
82626-48-0 |
5732 |
Synonyms:
Ambien
Ambien®|SL 80.0750-23N|SL-80.0750-23N|Stilnoct®
Amsic
Bikalm
Dalparan
Hypnogen
Myslee
N,N,6-Trimethyl-2-(4-methylphenyl)imidazo(1,2-a)pyridine-3-acetamide
N,N,6-Trimethyl-2-(4-methylphenyl)imidazo(1,2a)pyridine-3-acetamide hemitartrate
Sanval
SL 80.0750-23N
SL-80.0750-23N
Stilnoct
Stilnox
Zodormdura
|
Zoldem
Zolirin
Zolpi lich
ZOLPIDEM
Zolpidem 1a pharma
Zolpidem abz
Zolpidem ambien
ZOLPIDEM CIV
Zolpidem hemitartrate
Zolpidem tartrate
Zolpidemum
Zolpi-lich
Zolpimist
Zolpinox
|
|
2 |
|
Diphenhydramine |
Approved, Investigational |
Phase 4 |
|
147-24-0, 58-73-1 |
3100 |
Synonyms:
[2-(DIPHENYLMETHOXY)ETHYL]DIMETHYLAMINE
2-(Benzhydryloxy)-N,N-dimethylethylamine
2-Diphenylmethoxy-N,N-demthylethanamine
2-Diphenylmethoxy-N,N-dimethylethylamine
a-(2-Dimethylaminoethoxy)diphenylmethane
Alledryl
Allerdryl
Allergan
Allergina
alpha-(2-Dimethylaminoethoxy)diphenylmethane
ANTITUSSIVE
b-Dimethylaminoethanol diphenylmethyl ether
b-Dimethylaminoethyl benzhydryl ether
BELDIN
BELIX
Benadryl
BENADRYL PRESERVATIVE FREE
Benadryl®|benzhydramine|dimehydrinate
Bendylate
Benhydramin
Benylin
Benzantin
Benzhydramine
beta-Dimethylaminoethanol diphenylmethyl ether
beta-Dimethylaminoethyl benzhydryl ether
CALADRYL
Citrate, diphenhydramine
COLTEX
DIBENIL
Difenhidramina
Difenhydramine
Dimedrol
Dimedrolum
DIMEHYDRINATE
Dimethylamine benzhydryl ester
Diphamine
Diphantine
|
DIPHEN
DIPHENHYDRAMINE
Diphenhydramine citrate
Diphenhydramine citrate (1:1)
DIPHENHYDRAMINE HCL
Diphenhydramine hydrochloride
DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE
Diphenhydraminum
Diphenylhydramin
Diphenylhydramine
Dobacen
Dormin
DREEMON
DYTUSS
FEDRIL
GPPE COUGH EXPECT PAED
GPPE ORAL SOLN
HISTERGAN
HYDRAMINE
Hydrochloride, diphenhydramine
MEDINEX
N-(2-(Diphenylmethoxy)ethyl)-N,N-dimethylamine
NIGHTCALM
NSC-33299
NYTOL
NYTOL ONE-A-NIGHT
O-Benzhydryldimethylaminoethanol
PAXIDORM
Restamin
SILPHEN
SLEEPIA
SYNTEDRIL
TIXYLIX CATARRH
VICKS FORMULA 44
Α-(2-dimethylaminoethoxy)diphenylmethane
Β-dimethylaminoethanol diphenylmethyl ether
Β-dimethylaminoethyl benzhydryl ether
|
|
3 |
|
Suvorexant |
Approved, Investigational |
Phase 4 |
|
1030377-33-3 |
57505028 24965990 |
Synonyms:
BELSOMRA
Belsomra®|DORA-analogue|MK 4305|MK-4305
DORA-ANALOGUE
MK 4305
|
MK4305
MK-4305
SUVOREXANT
|
|
4 |
|
Promethazine |
Approved, Investigational |
Phase 4 |
|
60-87-7 |
4927 |
Synonyms:
(2-Dimethylamino-2-methyl)ethyl-N-dibenzoparathiazine
10-(2-Dimethylaminopropyl)phenothiazine
10-[2-(Dimethylamino)propyl]phenothiazine
Atosil
Diphergan
Diprazin
Hydrochloride, promethazine
Isopromethazine
Lilly 1516
N-(2'-Dimethylamino-2'-methyl)ethylphenothiazine
N,N,alpha-Trimethyl-10H-phenothiazine-10-ethanamine
N,N,a-Trimethyl-10H-phenothiazine-10-ethanamine
N,N,Α-trimethyl-10H-phenothiazine-10-ethanamine
NSC-30321
Phenargan
Phenergan
Phenergan®|Sominex®
Phensedyl
Pipolfen
Pipolphen
Proazaimine
Proazamine
|
Promazinamide
Promet
Prometazin
Prometazina
Prometazine
PROMETHACON
Promethazin
PROMETHAZINE
Promethazine hydrochloride
Promethazinum
PROMETHEGAN
Promethiazine
Promezathine
Prothazin
Prothazine
Pyrethia
Remsed
RP-3277
Rumergan
SOMINEX
ZIPAN-25
ZIPAN-50
|
|
5 |
|
Zoledronic acid |
Approved |
Phase 4 |
|
118072-93-8 |
68740 |
Synonyms:
(1-Hydroxy-2-(1H-imidazol-1-yl)ethylidene)bisphosphonate
(1-Hydroxy-2-(1H-imidazol-1-yl)ethylidene)bisphosphonic acid
(1-Hydroxy-2-imidazol-1-ylethylidene)diphosphonate
(1-Hydroxy-2-imidazol-1-ylethylidene)diphosphonic acid
2-(Imidazol-1-yl)-1-hydroxyethylidene-1,1-bisphosphonic acid
ácido zoledrónico
ACLASTA
Aclasta®|CGP-42446|CGP-42446A|Reclast®|zoledronate|Zometa®
ANHYDROUS ZOLEDRONIC ACID
CGP-42446
CGP-42446A
Novartis brand OF zoledronic acid
|
Reclast
ZERLINDA
ZOL
ZOL446
ZOLEDRONATE
Zoledronic acid
Zoledronic acid anhydrous
ZOLEDRONIC ACID HYDRATE
ZOLEDRONIC ACID MONOHYDRATE
ZOLEDRONIC ACID, ANHYDROUS
Zometa
Zometa Concentrate
|
|
6 |
|
Hypnotics and Sedatives |
|
Phase 4 |
|
|
|
7 |
|
GABA Agonists |
|
Phase 4 |
|
|
|
8 |
|
Orexin Receptor Antagonists |
|
Phase 4 |
|
|
|
9 |
|
Rivastigmine |
Approved, Investigational |
Phase 3 |
|
123441-03-2 |
77991 |
Synonyms:
(S)-3-(1-(Dimethylamino)ethyl)phenyl ethylmethylcarbamate
(S)-3-(1-(Dimethylamino)ethyl)phenyl ethylmethylcarbamic acid
(S)-N-Ethyl-3-((1-dimethyl-amino)ethyl)-N-methylphenylcarbamate
713, ENA
713, SDZ ENA
ALZEST
ELUDEN
ENA 713
Ena 713 free base
Ena 713 free base|Exelon®
ENA 713, SDZ
ENA713
ENA-713
ENA-713D
ERASTIG
Exelon
Exelon Patch
Hydrogen tartrate, rivastigmine
|
KERSTIPON
m-((S)-1-(Dimethylamino)ethyl)phenyl ethylmethylcarbamate
m-((S)-1-(Dimethylamino)ethyl)phenyl ethylmethylcarbamic acid
NIMVASTID
ONO-2540
Prometax
Rivastigmina
RIVASTIGMINE
Rivastigmine hydrogen tartrate
RivastigmineTartrate
SDZ ENA 713
SDZ-212713
SDZ-212-713
SDZ-ENA-713
SOMNITON
Tartrate, rivastigmine hydrogen
VOLEZE
|
|
10 |
|
Riluzole |
Approved, Investigational |
Phase 3 |
|
1744-22-5 |
5070 |
Synonyms:
2 Amino 6 trifluoromethoxybenzothiazole
2-Amino-6-trifluoromethoxybenzothiazole
Aventis behring brand OF riluzole
Aventis brand OF riluzole
BHV-0223
Impax brand OF riluzole
Rhone poulenc rorer brand OF riluzole
Rhone-poulenc rorer brand OF riluzole
Rilutek
|
Rilutek®|RP-54274|Tiglutik® (thickened oral suspension)
RILUZOL
RILUZOLE
Riluzole aventis brand
Riluzole impax brand
RILUZOLUM
RP-54274
TEGLUTIK
TIGLUTIK KIT
|
|
11 |
|
Rasagiline |
Approved |
Phase 3 |
|
136236-51-6 |
3052776 |
Synonyms:
(1R)-N-Propargylindan-1-amine
(R)-Indan-1-yl-prop-2-ynyl-amine
(R)-N-2-Propynyl-1-indanamine
2,3-Dihydro-N-2-propynyl-1H-inden-1-amine-(1R)-hydrochloride
AGN-1135
Azilect
Azilect®|TVP-1012
N-2-Propynyl-1-indanamine
N-Propargyl-1-aminoindan mesylate
|
RAS
Rasagilina
RASAGILINE
Rasagiline hydrochloride
TV-1030
TVP 101
TVP-101
TVP-1012
|
|
12 |
|
Ubidecarenone |
Approved, Investigational, Nutraceutical |
Phase 2, Phase 3 |
|
303-98-0 |
5281915 |
Synonyms:
(all-e)-2-(3,7,11,15,19,23,27,31,35,39-Decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaenyl)-5,6-dimethoxy-3-methyl-2,5-cyclohexadiene-1,4-dione
(all-e)-2,3-Dimethoxy-5-methyl-6-(3,7,11,15,19,23,27,31-octamethyl-2,6,10,14,18,22,26,30-dotriacontaoctaenyl)-2,5-cyclohexadiene-1,4-dione
2-((all-e)-3,7,11,15,19,23,27,31,35,39-Decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaenyl)-5,6-dimethoxy-3-methyl-p-benzoquinone
2-(3,7,11,15,19,23,27,31,35,39-Decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaenyl)-5,6-dimethoxy-3-methyl-p-benzoquinone
2,3-Dimethoxy-5-methyl-6-decaprenylbenzoquinone
2-[(2E,6E,10E,14E,18E,22E,26E,30E,34E)-3,7,11,15,19,23,27,31,35,39-Decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaenyl]-5,6-dimethoxy-3-methyl- 2,5-cyclohexadiene-1,4-dione
2-[(2E,6E,10E,14E,18E,22E,26E,30E,34E)-3,7,11,15,19,23,27,31,35,39-Decamethyltetraconta-2,6,10,14,18,22,26,30,34,38-decaen-1-yl]-5,6-dimethoxy-3-methyl-1,4-benzoquinone
4-Ethyl-5-fluoropyrimidine
Adelir
all-trans-Ubiquinone
API 31510
API-31510
Aqua Q 10l10
Aqua Q10
Bio-quinon
Bio-quinone Q10
Coenzyme Q10
Coenzyme Q-10
CO-Enzyme Q10
CoQ
CoQ 10
CoQ10
Ensorb
Kaneka Q10
|
Kudesan
Li-Q-sorb
Liquid-Q
Neuquinon
Neuquinone
NSC-140665
NSC-140865
PureSorb Q 40
Q
Q 10AA
Q 199
Q10
Q-Gel
Q-Gel 100
Q-Ter
Ubidecarenone
UBIDECARENONE FOR SYSTEM SUITABILITY
Ubiquinone
Ubiquinone 10
Ubiquinone 50
Ubiquinone Q10
UBIQUINONE-10
Unbiquinone
Unispheres Q 10
|
|
13 |
|
Vitamins |
|
Phase 2, Phase 3 |
|
|
|
14 |
|
Trace Elements |
|
Phase 2, Phase 3 |
|
|
|
15 |
|
Ubiquinone |
|
Phase 2, Phase 3 |
|
|
|
16 |
|
Micronutrients |
|
Phase 2, Phase 3 |
|
|
|
17 |
|
Cholinesterase Inhibitors |
|
Phase 3 |
|
|
|
18 |
|
Cholinergic Agents |
|
Phase 3 |
|
|
|
19 |
|
Neurotransmitter Agents |
|
Phase 3 |
|
|
|
20 |
|
Anticonvulsants |
|
Phase 3 |
|
|
|
21 |
|
Neuroprotective Agents |
|
Phase 3 |
|
|
|
22 |
|
Excitatory Amino Acid Antagonists |
|
Phase 3 |
|
|
|
23 |
|
Protective Agents |
|
Phase 3 |
|
|
|
24 |
|
Monoamine Oxidase Inhibitors |
|
Phase 3 |
|
|
|
25 |
|
Donepezil |
Approved |
Phase 2 |
|
120014-06-4 |
3152 |
Synonyms:
1-Benzyl-4-((5,6-dimethoxy-1-indanon)-2-yl)methylpiperidine hydrochloride
Aricept
Aricept odt
Aricept®|E-2020
Domepezil
Donaz
Donepezil
|
Donepezil hydrochloride
Donepezilium oxalate trihydrate
Donepezilo
Donepezilum
E-2020
Eranz
|
|
26 |
|
Valproic acid |
Approved, Investigational |
Phase 2 |
|
99-66-1 |
3121 |
Synonyms:
(N-C3H7)2chcooh
(S)-2-Propyl-4-pentanoate
(S)-2-Propyl-4-pentanoic acid
2 Propylpentanoic acid
2-N-PROPYL-4-PENTENOIC ACID
2-N-Propyl-N-valerate
2-N-Propyl-N-valeric acid
2-Propylpentanoate
2-PROPYL-pentanoate
2-Propylpentanoic acid
2-PROPYL-pentanoIC ACID
2-Propylvalerate
2-Propylvaleric acid
44089
4-Heptanecarboxylate
4-Heptanecarboxylic acid
A-44090
A-44090|Depakote®|Epilim®|valproate sodium
Acetate, dipropyl
Acid, propylisopropylacetic
Acid, valproic
Acide valproique
acide valproïque
Acido valproico
ácido valproico
Acidum valproicum
Alti-valproic
Apo-divalproex
Apo-valproic
Apo-valproic syrup
Avugane
Baceca
Calcium valproate
Calcium, valproate
Convulex
Convulsofin
Delepsine
Depacon
Depakene
Depakin
Depakin chrono
Depakine
Depakine chrono
Depakote
Deproic
Di-N-propylacetate
Di-N-propylacetic acid
Di-N-propylessigsaeure
Di-N-propylessigsaure
Di-n-propylessigsäure
Dipropyl acetate
Dipropylacetate
Dipropylacetic acid
Divalproex
Divalproex sodium
DOM-divalproex
Dom-valproate
DOM-valproic
Dom-valproic acid
DOM-valproic acid e.c.
Dom-valproic acid syrup
DPA
Epiject i.v.
Epilex
Epilim
|
Epival
Epival er
Ergenyl
Gen-divalproex
Kyselina 2-propylvalerova
LEP321
Magnesium valproate
Med valproic
Mylproin
Myproate
Myproic acid
N-Dipropylacetic acid
N-DPA
Novo-divalproex
Novo-valproic
Novo-valproic - ecc
Novo-valproic soft gel cap
NSC-93819
Nu-valproic
PEAC
Penta-valproic
PHL-Valproate
PHL-Valproic acid
PHL-Valproic acid e.c.
PMS-Divalproex
PMS-Valproate
PMS-Valproic acid
PMS-Valproic acid e.c.
Propylisopropylacetic acid
Propylvaleric acid
Ratio-valproic - ecc
S(-)-4-En-valproate
S(-)-4-En-valproic acid
S-2-N-Propyl-4-pentenoate
S-2-N-Propyl-4-pentenoic acid
Sandoz valproic
Savicol
Semisodium valproate
Sodium hydrogen divalproate
Sodium valproate
Sodium, divalproex
Sodium, valproate
Sprinkle
STAVZOR
Valcote
Valparin
Valproate
Valproate calcium
Valproate semisodique [French]
Valproate semisodium
Valproate sodium
Valproate, calcium
Valproate, magnesium
Valproate, semisodium
Valproate, sodium
Valproato semisodico [Spanish]
Valproatum seminatricum [Latin]
VALPROIC ACID
Valproic acid usp
Valproic acid USP24
Valproic acid, sodium salt (2:1)
Valproinsaeure
Valproinsäure
VPA
Vupral
|
|
27 |
|
Lithium carbonate |
Approved |
Phase 1, Phase 2 |
|
554-13-2 |
|
Synonyms:
CAMCOLIT 250
CAMCOLIT 400
Carbonic acid, dilithium salt
CP-1546761
CP-15467-61
Dilithium carbonate
ESKALITH
ESKALITH CR
LISKONUM
|
LITHANE
Lithii carbonas
LITHIUM CARBONATE
LITHOBID
LITHONATE
LITHOTABS
NSC-16895
PHASAL
|
|
28 |
|
Acetylcarnitine |
Approved, Investigational |
Phase 1, Phase 2 |
|
3040-38-8 |
|
Synonyms:
(-)-Acetylcarnitine
(+-)-Acetylcarnitine
(3R)-3-Acetyloxy-4-(trimethylazaniumyl)butanoate
(R)-Acetylcarnitine
3-(Acetyloxy)-4-(trimethylammonio)butanoate
3-(Acetyloxy)-4-(trimethylammonio)butanoic acid
Acetyl carnitine
Acetyl L carnitine
Acetylcarnitine
Acetyl-carnitine
Acetylcarnitine, (R)-isomer
Acetyl-DL-carnitine
Acetyl-L-(-)-carnitine
Acetyl-L-carnitine
ALC
|
ALCAR
Branigen
C2 Carnitine
Carnitine, acetyl
DL-O-Acetylcarnitine
L-Acetylcarnitine
L-Carnitine acetyl ester
Levocarnitine acetyl
L-O-Acetylcarnitine
Medosan
Nicetile
O-Acetyl-(R)-carnitine
O-Acetylcarnitine
O-Acetyl-L-carnitine
R-Acetylcarnitine
|
|
29 |
|
Tolfenamic acid |
Approved, Investigational |
Phase 1, Phase 2 |
|
13710-19-5 |
610479 |
Synonyms:
Acide tolfenamique
Acido tolfenamico
ácido tolfenámico
Acidum tolfenamicum
Bifenac
Clotam
CLOTAM RAPID
Clotam®
N-(2-Methyl-3-chlorophenyl)anthranilate
N-(2-Methyl-3-chlorophenyl)anthranilic acid
N-(3-Chloro-2-methylphenyl)anthranilate
|
N-(3-Chloro-2-methylphenyl)anthranilic acid
N-(3-Chloro-O-tolyl)-anthranilate
N-(3-Chloro-O-tolyl)anthranilic acid
N-(3-Chloro-O-tolyl)-anthranilic acid
Pharmacia brand OF tolfenamic acid
Provalis brand OF tolfenamic acid
Rociclyn
Tolfenamate
TOLFENAMIC ACID
Zambon brand OF tolfenamic acid
|
|
30 |
|
Benzocaine |
Approved, Investigational |
Phase 2 |
|
1994-09-7, 94-09-7 |
2337 |
Synonyms:
(P-(Ethoxycarbonyl)phenylamine
4-(Ethoxycarbonyl)aniline
4-(Ethoxycarbonyl)phenylamine
4-Aminobenzoate
4-Aminobenzoate ethyl ester
4-Aminobenzoic acid
4-Aminobenzoic acid ethyl ester
4-Carbethoxyaniline
Acetate, benzocaine
Aethoform
AEZODENT
Amben ethyl ester
Americaine
Anaesthan-syngala
Anaesthesin
Anaesthin
Anestezin
Anesthesin
Anesthesine
Anesthone
ANTHISAN PLUS
AR01
AR-01
Baby anbesol
Bensokain
Benzoak
Benzocaina
BENZOCAINE
Benzocaine acetate
Benzocaine formate
Benzocaine hydrobromide
Benzocaine hydrochloride
Benzocaine methanesulfonate
Benzocainum
BURNEZE
CHILDREN'S CHLORASEPTIC
DEQUACAINE
Dermoplast
Diet ayds
Ethoform
Ethyl 4-aminobenzoate
|
Ethyl 4-aminobenzoic acid
Ethyl aminobenzoate
Ethyl aminobenzoic acid
Ethyl P-aminobenzenecarboxylate
Ethyl p-aminobenzoate
Ethyl p-aminobenzoic acid
Ethyl p-aminophenylcarboxylate
Ethyl p-aminophenylcarboxylic acid
Ethylester kyseliny P-aminobenzoove
Formate, benzocaine
Hurricaine
Hydrobromide, benzocaine
Hydrochloride, benzocaine
Identhesin
Keloform
LANACANE
MEDILAVE
Methanesulfonate, benzocaine
NESTOSYL
Norcain
Norcaine
NSC-41531
NSC-4688
Orabase-b
Ora-jel
ORAJEL
Orthesin
p-(Ethoxycarbonyl)aniline
P-Aminobenzoate
P-Aminobenzoic acid
P-Aminobenzoic acid ethyl ester
Parathesin
Parathesine
p-Carbethoxyaniline
p-Ethoxycarboxylic aniline
Slim mint gum
Solarcaine
Solu H
Topcaine
TYROSOLVEN
TYROZETS
|
|
31 |
|
Tannic acid |
Approved |
Phase 2 |
|
1401-55-4 |
16129878 16129778 |
Synonyms:
Acid, tannic
ácido tánico
Acids, tannic
E181
FEMA NO. 3042
Gallotannic acid
|
Gallotannin
NSC-656273
TANNIC ACID
Tannic acids
Tannins
|
|
32 |
|
Folic acid |
Approved, Nutraceutical, Vet_approved |
Phase 1, Phase 2 |
|
59-30-3 |
6037 |
Synonyms:
(2S)-2-[(4-{[(2-AMINO-4-OXO-1,4-DIHYDROPTERIDIN-6-YL)METHYL]AMINO}PHENYL)FORMAMIDO]PENTANEDIOIC ACID
(2S)-2-[[[4-[(2-AMINO-4-OXO-1H-PTERIDIN-6-YL)METHYLAMINO]PHENYL]-OXO-METHYL]AMINO]PENTANEDIOIC ACID
(2S)-2-[[4-[(2-AMINO-4-OXO-1H-PTERIDIN-6-YL)METHYLAMINO]BENZOYL]AMINO]GLUTARIC ACID
(2S)-2-[[4-[(2-AMINO-4-OXO-1H-PTERIDIN-6-YL)METHYLAMINO]BENZOYL]AMINO]PENTANEDIOIC ACID
(2S)-2-[[4-[(2-AMINO-4-OXO-1H-PTERIDIN-6-YL)METHYLAMINO]PHENYL]CARBONYLAMINO]PENTANEDIOIC ACID
[<sup>3</sup>H]-folic acid
Acide folique
ácido fólico
Acidum folicum
ACIFOLIC
Apo-Folic
B03BB01
b9, Vitamin
BIO SCIENCE
CYTOFOL
DOSFOLAT B ACTIV
FOLACID
FOLACIN
FOLATE
FOLBAL
FOLCIDIN
FOLDINE
FOLETTES
FOLIAMIN
FOLIC ACID
Folic acid, (D)-isomer
Folic acid, (DL)-isomer
Folic acid, calcium salt (1:1)
Folic acid, monopotassium salt
Folic acid, monosodium salt
Folic acid, potassium salt
Folic acid, sodium salt
FOLICARE
FOLICET
FOLIPAC
|
FOLSAEURE
FOLSAN
FOLSAURE
Folsäure
FOLSAV
FOLVITE
Folvron
INCAFOLIC
LEXPEC
LIVER LACTOBACILLUS CASEI FACTOR
MILLAFOL
N-(4-{[(2-AMINO-4-OXO-3,4-DIHYDROPTERIDIN-6-YL)METHYL]AMINO}BENZOYL)-L-GLUTAMIC ACID
N-[(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamate
N-[(4-{[(2-AMINO-4-OXO-1,4-DIHYDROPTERIDIN-6-YL)METHYL]AMINO}PHENYL)CARBONYL]-L-GLUTAMIC ACID
N-[4-[[(2-AMINO-3,4-DIHYDRO-4-OXO-6-PTERIDINYL)METHYL]AMINO]BENZOYL]-L-GLUTAMIC ACID
NATUR FLOW
N-Pteroyl-L-glutamate
N-PTEROYL-L-GLUTAMIC ACID
NSC-3073
PGA
PRECONCEIVE
PTEGLU
PTEROYLGLUTAMATE
PTEROYLGLUTAMIC ACID
PTEROYL-L-GLUTAMATE
PTEROYL-L-GLUTAMIC ACID
PTEROYL-L-MONOGLUTAMATE
PTEROYL-L-MONOGLUTAMIC ACID
PTEROYLMONOGLUTAMIC ACID
ROCHE
Vitamin B9
VITAMIN BC
VITAMIN BE
VITAMIN M
|
|
33 |
|
Lipoic acid |
Approved, Investigational, Nutraceutical |
Phase 1, Phase 2 |
|
1200-22-2 |
864 6112 |
Synonyms:
(+)-a-Lipoate
(+)-a-Lipoic acid
(+)-alpha-Lipoate
(+)-alpha-Lipoic acid
(+)-α-lipoate
(+)-α-lipoic acid
(3R)-1,2-Dithiolane-3-pentanoic acid
(R)-(+)-1,2-Dithiolane-3-pentanoic acid
(R)-(+)-alpha-Lipoic acid
(R)-(+)-Lipoate
(R)-(+)-Lipoic acid
(R)-(+)-α-Lipoic acid
(R)-1,2-Dithiolane-3-pentanoate
(R)-1,2-Dithiolane-3-pentanoic acid
(R)-1,2-Dithiolane-3-valerate
(R)-1,2-Dithiolane-3-valeric acid
(R)-5-(1,2-Dithiolan-3-yl)pentanoicacid
(R)-6,8-Thioctate
(R)-6,8-Thioctic acid
(R)-alpha-Lipoic acid
(R)-Lipoate
(R)-Lipoic acid
(R)-α-Lipoic acid
1,2-Dithiolane-3-pentanoate
1,2-Dithiolane-3-pentanoic acid
1,2-Dithiolane-3R-pentanoate
1,2-Dithiolane-3R-pentanoic acid
1,2-Dithiolane-3-valerate
1,2-Dithiolane-3-valeric acid
5-(1,2-Dithiolan-3-yl)pentanoic acid
5-(1,2-Dithiolan-3-yl)valerate
5-(1,2-Dithiolan-3-yl)valeric acid
5-(3-DITHIOLANYL)PENTANOIC ACID
5-(DITHIOLAN-3-YL)PENTANOIC ACID
5-(Dithiolan-3-yl)valerate
5-(Dithiolan-3-yl)valeric acid
5-[3-(1,2-Dithiolanyl)]pentanoate
5-[3-(1,2-Dithiolanyl)]pentanoic acid
6,8-Thioctate
6,8-Thioctic acid
6,8-Thiotate
6,8-Thiotic acid
6-Thioctate
6-Thioctic acid
6-Thiotate
6-Thiotic acid
Acetate-replacing factor
Acetic acid-replacing factor
Acid, alpha-lipoic
ALA
a-Lipoate
a-Lipoic acid
a-Liponsaeure
Aliud brand OF thioctic acid
Alpha Lipogamma
alpha Lipoic acid
Alpha Lipon stada
alpha Liponaure heumann
Alpha Liponsaure sofotec
alpha Liponsaure von CT
Alpha Lippon al
alpha Vibolex
alpha-(+)-Lipoic acid
Alphaflam
alpha-Lipoate
AlphaLipogamma
Alpha-Lipogamma
alpha-Lipoic acid
AlphaLipon stada
Alpha-Lipon stada
alpha-Liponaure heumann
AlphaLiponaure heumann
alpha-Liponsaeure
ALPHA-LIPONSÄURE
AlphaLiponsaure sofotec
Alpha-Liponsaure sofotec
alpha-Liponsaure von CT
AlphaLiponsaure von CT
AlphaLippon al
Alpha-Lippon al
alpha-Vibolex
AlphaVibolex
Azulipont
Azupharma brand OF thioctic acid
Biletan
biomo Brand OF thioctic acid
Biomo lipon
Biomolipon
Biomo-lipon
CT Arzneimittel brand OF thioctic acid
CT-Arzneimittel brand OF thioctic acid
|
DL-a-Lipoate
DL-a-Lipoic acid
DL-alpha-Lipoate
DL-alpha-Lipoic acid
DL-Thioctate
DL-Thioctic acid
DL-Α-lipoate
DL-Α-lipoic acid
D-thioctic acid
Duralipon
Espa lipon
Espalipon
Espa-lipon
Esparma brand OF thioctic acid
Fenint
Generosan brand OF thioctic acid
Heumann brand OF thioctic acid
Hexal brand OF thioctic acid
Illa brand OF thioctic acid
Illa brand OF thioctic acid tromethamine
Injekt, thiogamma
Juta brand OF thioctic acid
Juthiac
Lichtenstein brand OF thioctic acid
Lipoate
Lipoic acid
LIPOIC ACID, ALPHA
Liponate
Liponic acid
Liponsaure ratiopharm
Liponsaureratiopharm
Liponsaure-ratiopharm
Merck dura brand OF thioctic acid
MTW Alphaliponsaure
MTW Brand OF thioctic acid
MTWAlphaliponsaure
MTW-Alphaliponsaure
Neurium
NSC-628502
NSC-90788
Pharmacia brand OF thioctic acid
Pleomix Alpha
Pleomix Alpha N
PleomixAlpha
Pleomix-Alpha
PleomixAlpha N
Pleomix-Alpha N
Q Pharm brand OF thioctic acid
Q-Pharm brand OF thioctic acid
R-(+)-Lipoate
R-(+)-Lipoic acid
R-(+)-thioctic acid
R-alpha-lipoic acid
Ratiopharm brand OF thioctic acid
RLA
R-LA
Rosen brand OF thioctic acid
Sofotec brand OF thioctic acid
Stadapharm brand OF thioctic acid
Thioctacid
Thioctacide T
Thioctansaeure
THIOCTANSÄURE
Thioctate
Thioctate D-form
Thioctic acid
Thioctic acid D-form
THIOCTIC ACID DL-FORM
Thioctsaeure
THIOCTSÄURE
Thiogamma injekt
Thiogamma oral
Thioktsaeure
THIOKTSÄURE
Thiotomin
TIOCTIC ACID
Tromlipon
Trommsdorgg brand OF thioctic acid
Verla brand OF thioctic acid
Verla lipon
Verla-lipon
VerlaLipon
Viatris brand OF thioctic acid
Viatris brand OF thioctic acid tromethamine
Worwag brand OF thioctic acid
Worwag brand OF thioctic acid meglumine
α-(+)-Lipoic acid
Α-lipoate
Α-lipoic acid
Α-liponsaeure
|
|
34 |
|
(3-Carboxy-2-(R)-Hydroxy-Propyl)-Trimethyl-Ammonium |
Experimental |
Phase 1, Phase 2 |
|
461-06-3 |
|
Synonyms:
CARNITINE
CARNITINE CHLORIDE
|
|
|
35 |
|
Fasudil |
Investigational |
Phase 2 |
|
103745-39-7 |
3547 |
Synonyms:
1-(5-Isoquinolinesulfonyl)homopiperazine
5-(1,4-Diazepan-1-sulphonyl)isoquinoline
5-(1,4-Diazepane-1-sulphonyl)isoquinoline
AT 877
AT-877
dihydrochloride fasudil|HA 1077|HA1077
FASUDIL
|
Fasudil hydrochloride
Fasudil mesylate
HA 1077
HA1077
HA-1077
HA-1077at-877fasudil
ZK-258594
|
|
36 |
|
Tilavonemab |
Investigational |
Phase 2 |
|
2096513-89-0 |
|
Synonyms:
Immunoglobulin g4, anti-(human tau protein) (human-mus musculus monoclonal pr-1649264 .gamma.4-chain), disulfide with human-mus musculus monoclonal pr-1649264 .kappa.-chain, dimer
|
|
|
37 |
|
Psychotropic Drugs |
|
Phase 2 |
|
|
|
38 |
|
Antidepressive Agents |
|
Phase 1, Phase 2 |
|
|
|
39 |
|
Folate |
|
Phase 1, Phase 2 |
|
|
|
40 |
|
Vitamin B9 |
|
Phase 1, Phase 2 |
|
|
|
41 |
|
Vitamin B Complex |
|
Phase 1, Phase 2 |
|
|
|
42 |
|
Alpha-lipoic Acid |
|
Phase 1, Phase 2 |
|
|
|
43 |
|
Linoleate |
|
Phase 2 |
|
|
|
44 |
|
Vasodilator Agents |
|
Phase 2 |
|
|
|
45 |
|
Protein Kinase Inhibitors |
|
Phase 2 |
|
|
|
46 |
|
Analgesics |
|
Phase 1, Phase 2 |
|
|
|
47 |
|
Antirheumatic Agents |
|
Phase 1, Phase 2 |
|
|
|
48 |
|
Hormones |
|
Phase 1, Phase 2 |
|
|
|
49 |
|
Hormone Antagonists |
|
Phase 1, Phase 2 |
|
|
|
50 |
|
Calcium, Dietary |
|
Phase 1, Phase 2 |
|
|
|
Interventional clinical trials:
(show top 50)
(show all 120)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Treatment of Disturbed Sleep in Progressive Supranuclear Palsy (PSP) |
Recruiting |
NCT04014387 |
Phase 4 |
Suvorexant;Zolpidem;Placebo oral capsule |
2 |
TOPAZ: Trial of Parkinson's And Zoledronic Acid A Randomized Placebo-controlled Trial of Zoledronic Acid for the Prevention of Fractures in Patients With Parkinson's Disease |
Recruiting |
NCT03924414 |
Phase 4 |
Zoledronic Acid 5Mg/Bag 100Ml Inj |
3 |
A Multicentre, Phase 3, Clinical Study to Compare the Striatal Uptake of a Dopamine Transporter Radioligand, DaTSCAN™ Ioflupane (123I) Injection, After Intravenous Administration to Chinese Patients With a Diagnosis of Parkinson's Disease, Multiple System Atrophy, Progressive Supranuclear Palsy, or Essential Tremor and to Healthy Controls |
Completed |
NCT04193527 |
Phase 3 |
DaTSCAN™ Ioflupane (123I) Injection |
4 |
A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy |
Completed |
NCT01110720 |
Phase 2, Phase 3 |
Davunetide;Placebo |
5 |
Effects of Coenzyme Q10 in PSP and CBD, A Randomized, Placebo-Controlled, Double Blind Cross Over Pilot Study |
Completed |
NCT00532571 |
Phase 2, Phase 3 |
CoQ10 |
6 |
RIVA-PSP: Efficacy of Rivastigmine on Motor, Cognitive and Behavioural Impairment in Progressive Supranuclear Palsy: A Randomised Double Blind Placebo-controlled Clinical Trial |
Active, not recruiting |
NCT02839642 |
Phase 3 |
Rivastigmine;Placebo |
7 |
Phase 3 Study of Riluzole in Multiple System Atrophy (MSA) and Progressive Supranuclear Palsy (PSP) (Parkinson's Plus Syndromes) |
Terminated |
NCT00211224 |
Phase 3 |
Riluzole |
8 |
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Rasagiline in Subjects With Progressive Supranuclear Palsy (Phase III) |
Terminated |
NCT01187888 |
Phase 3 |
Rasagiline;Sugar pill |
9 |
Study of the Distractibility Syndrome in Patients With Progressive Supranuclear Palsy |
Unknown status |
NCT00139373 |
Phase 2 |
donepezil |
10 |
Autologous Mesenchymal Stem Cell Therapy in Progressive Supranuclear Palsy: a Randomized, Double-blind, Controlled Clinical Trial |
Unknown status |
NCT01824121 |
Phase 1, Phase 2 |
|
11 |
Rivastigmine (Exelon®) for Treatment of Dementia in Patient With Progressive Supranuclear Paresis Open Label Phase 2 Study |
Unknown status |
NCT00522015 |
Phase 2 |
rivastigmine |
12 |
A Pilot Exploratory, Randomised, Placebo-controlled, Double Blinded, Cross-over , Phase 2a Study to Explore Efficacy and Safety of NBMI Treatment in Patients With Progressive Supranuclear Palsy (PSP) or Multiple System Atrophy (MSA) |
Completed |
NCT04184063 |
Phase 2 |
NBMI |
13 |
Randomized Placebo-controlled Trial of Valproic Acid in Patients With Progressive Supranuclear Palsy |
Completed |
NCT00385710 |
Phase 2 |
valproic acid;Placebo |
14 |
A Pilot Trial of Lithium in Subjects With Progressive Supranuclear Palsy or Corticobasal Degeneration |
Completed |
NCT00703677 |
Phase 1, Phase 2 |
Lithium |
15 |
Mono-center, Prospective, Double-blind, Placebo-controlled, Randomized Clinical Phase IIa Trial to Assess the Safety, Tolerability, and Immediate Biological Effects of Coenzyme Q10 - nanoQuinon® in Progressive Supranuclear Palsy |
Completed |
NCT00328874 |
Phase 2 |
Coenzyme Q10 |
16 |
An Open-label Trial of Alpha-lipoic Acid/L-acetyl Carnitine for Progressive Supranuclear Palsy (PSP): Effect Upon Oxidative Damage and Mitochondrial Biomarkers |
Completed |
NCT01537549 |
Phase 1, Phase 2 |
alpha-lipoic acid and L-acetyl carnitine |
17 |
Dose-Escalation Trial of Continuously Infused Recombinant-Methionyl Human Glial Cell Line-Derived Neurotrophic Factor for the Treatment of PSP |
Completed |
NCT00005903 |
Phase 2 |
GDNF & Synchro Med Infusion System |
18 |
A Randomized, Double-blind, Controlled, Phase 2 Study to Assess Efficacy, Long Term Safety and Tolerability of RT001 in Subjects With Progressive Supranuclear Palsy |
Recruiting |
NCT04937530 |
Phase 2 |
RT001;Placebo |
19 |
A Phase 2a Open-Label Preliminary Safety, Tolerability, and Biomarker Study of Oral Fasudil in Patients With the 4-Repeat Tauopathies of Progressive Supranuclear Palsy-Richardson Syndrome or Corticobasal Syndrome. |
Active, not recruiting |
NCT04734379 |
Phase 2 |
Fasudil |
20 |
A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess Tolerability, Safety, Pharmacokinetics and Effect of AZP2006 on Cerebrospinal Fluid Biomarkers in 36 Patients With Progressive Supranuclear Palsy |
Active, not recruiting |
NCT04008355 |
Phase 2 |
AZP2006 oral solution;Placebo oral solution |
21 |
A Phase 2a Study of TPN-101 in Patients With Progressive Supranuclear Palsy (PSP) |
Active, not recruiting |
NCT04993768 |
Phase 2 |
TPN-101, 100 mg/day;TPN-101, 200 mg/day;TPN-101, 400 mg/day;Placebo |
22 |
A Phase 2a Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Tolfenamic Acid for the Treatment of Progressive Supranuclear Palsy |
Not yet recruiting |
NCT04253132 |
Phase 1, Phase 2 |
Tolfenamic Acid;Placebos |
23 |
A Randomized, Double-Blind, Placebo-Controlled Multiple Dose Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Progressive Supranuclear Palsy |
Terminated |
NCT02985879 |
Phase 2 |
Placebo;ABBV-8E12 |
24 |
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Intravenously Administered BIIB092 in Participants With Progressive Supranuclear Palsy |
Terminated |
NCT03068468 |
Phase 2 |
BIIB092;Placebo |
25 |
An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP) |
Terminated |
NCT03391765 |
Phase 2 |
ABBV-8E12;Placebo solution for IV infusion on Day 15 |
26 |
Safety and Efficacy of Droxidopa for Fatigue in Patients With Parkinsonism |
Withdrawn |
NCT03446807 |
Phase 2 |
Droxidopa;Placebo Oral Tablet |
27 |
A Participant-Blind, Investigator-Blind, Placebo-Controlled, Phase 1b Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of UCB0107 in Study Participants With Progressive Supranuclear Palsy (PSP) |
Completed |
NCT04185415 |
Phase 1 |
bepranemab;Placebo |
28 |
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Sequential Cohort, Dose-Ranging Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of TPI 287 in Patients With Primary Four Repeat Tauopathies: Corticobasal Syndrome or Progressive Supranuclear Palsy |
Completed |
NCT02133846 |
Phase 1 |
TPI 287 2 mg/m2;TPI-287 20 mg/m2;Placebo;TPI-287 6.3 mg/m2 |
29 |
Extension Study of ABBV-8E12 in Patients With Progressive Supranuclear Palsy (PSP) Who Completed Study C2N-8E12-WW-104 |
Completed |
NCT03413319 |
Phase 1 |
ABBV-8E12 |
30 |
A 6 Month, Open-Label, Pilot Futility Clinical Trial of Oral Salsalate for Progressive Supranuclear Palsy |
Completed |
NCT02422485 |
Phase 1 |
Salsalate |
31 |
A Double-Blind, Placebo Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of C2N-8E12 in Subjects With Progressive Supranuclear Palsy |
Completed |
NCT02494024 |
Phase 1 |
Single dose C2N-8E12;Single dose placebo |
32 |
A 6 Month, Open-Label, Pilot Futility Clinical Trial of Monthly Young Healthy Male Donor Plasma Transfusions for Progressive Supranuclear Palsy |
Completed |
NCT02460731 |
Phase 1 |
|
33 |
A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study of Intravenously Administered BMS-986168 in Patients With Progressive Supranuclear Palsy |
Completed |
NCT02460094 |
Phase 1 |
BIIB092;Placebo |
34 |
18F-AV-1451 Injection for Brain Imaging of Tau in Subjects With Progressive Supranuclear Palsy (PSP), Subjects With Corticobasal Degeneration (CBD) and Healthy Volunteers |
Completed |
NCT02167594 |
Phase 1 |
Flortaucipir F18 |
35 |
Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Clinically Diagnosed Tauopathies in Comparison to Healthy Subjects |
Completed |
NCT02103894 |
Phase 1 |
[18F]T807 ([18F]MNI-777) |
36 |
Phase 1 Test-retest Evaluation of [18F]MNI-958 PET as an Imaging Marker for Tau Protein in the Brain of Patients With Alzheimer's Disease and Probable PSP as Compared to Healthy Volunteers |
Completed |
NCT03545789 |
Phase 1 |
[18F]MNI-958 |
37 |
A 12 Week Randomized, Double Blind, Placebo-Controlled Pilot Study of Davunetide (NAP, AL-108) in Predicted Tauopathies |
Completed |
NCT01056965 |
Phase 1 |
davunetide (AL-108, NAP);Placebo nasal spray |
38 |
An Open Label, Single Center Study to Evaluate the Safety and Imaging Characteristics of [18F]PI-2620 as PET Radioligand for Imaging Tau Deposition in the Brains of Patients With Mild to Moderate Alzheimer's Disease (AD) and Patients With Progressive Supranuclear Palsy (PSP) After i.v. Application of [18F]PI-2620 With High and Low Specific Activity |
Recruiting |
NCT04715750 |
Phase 1 |
[18F]-PI2620 |
39 |
An Open Label, Single Center Study to Evaluate the Safety and Test-retest Characteristics of [18F]PI-2620 as PET Radioligand for Imaging Tau Deposition in the Brains of Patients With Progressive Supranuclear Palsy Richardson Syndrome (PSP-RS) Compared to Non-demented Controls (NDC) |
Recruiting |
NCT05187546 |
Phase 1 |
[18F]-PI2620 |
40 |
Evaluation of [18F]APN-1607 as a PET Biomarker for Longitudinal Change in Tau Pathology in Participants With Progressive Supranuclear Palsy |
Recruiting |
NCT05005819 |
Phase 1 |
[18F] APN-1607 |
41 |
A Randomized, Participant, Investigator and Sponsor Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of Intrathecally Administered NIO752 in Participants With Progressive Supranuclear Palsy |
Recruiting |
NCT04539041 |
Phase 1 |
antisense oligonucleotide;placebo |
42 |
An Open-Label Extension Study to Evaluate the Safety and Tolerability of Long-Term UCB0107 Administration in Study Participants With Progressive Supranuclear Palsy |
Active, not recruiting |
NCT04658199 |
Phase 1 |
UCB0107 (bepranemab) |
43 |
A Multicenter, Open-Label, Long-Term Treatment Study of Intravenously Administered BIIB092 in Patients With Progressive Supranuclear Palsy Who Participated in Study CN002003 |
Terminated |
NCT02658916 |
Phase 1 |
BIIB092 |
44 |
Functional Assessment of the Melanopsin-Containing Retinal Ganglion Cells in Progressive Supranuclear Palsy Using Chromatic Pupillometry |
Unknown status |
NCT03330353 |
|
|
45 |
Cross-sectional Study of the Factors Determining the Quality of Life of the Patient and the Burden of the Caregiver in Progressive Supranuclear Palsy |
Unknown status |
NCT03638505 |
|
|
46 |
Observational Longitudinal Study of Magnetic Resonance Imaging, Specimen Biomarkers, and Clinical Progression in Progressive Supranuclear Palsy and Corticobasal Degeneration |
Unknown status |
NCT01804452 |
|
|
47 |
Multimodal Assessment For Predicting Specific Pathological Substrate in Frontotemporal Lobar Degeneration |
Unknown status |
NCT02964637 |
|
|
48 |
Blood Alpha-Synuclein, Gene Expression, and Smell Testing as Diagnostic and Prognostic Biomarkers in Parkinson's Disease |
Unknown status |
NCT00653783 |
|
|
49 |
A Multi-centre Proof-of-performance Clinical Study to Validate Blood-based Biomarker Candidates for the Diagnosis of Alzheimer's Disease |
Unknown status |
NCT03030586 |
|
|
50 |
Cerebellar rTMS Theta Burst for Postural Instability in Progressive Supranuclear Palsy: a Double Blind Cross-over Sham-controlled Study Using Wearing Sensors Technology |
Completed |
NCT04222218 |
|
|
|